Dec 30, 2025
- Corporate
[Update on Disclosed Matter] Notice Concerning Completion of Making Renalys Pharma, Inc. a Wholly-Owned Subsidiary and an Absorption-Type Merger
| Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
| Code number: | 4519 (Prime Market of Tokyo Stock Exchange) |
| Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
| President & CEO: | Osamu Okuda |
| Inquiries to: | Kae Miyata |
| Head of Corporate Communications Dept. | |
| Tel: | |
| For media:+81-(0)3-3273-0881 | |
| For investors:+81-(0)3-3273-0554 |
TOKYO, December 30, 2025 -- Chugai Pharmaceutical Co., Ltd. made Renalys Pharma, Inc. a wholly-owned subsidiary on November 27, 2025, as previously announced in the news release titled “Notice of Absorption-Type Merger of a Wholly-Owned Subsidiary, Renalys Pharma, Inc.” issued on November 18, 2025. Following this, Chugai announced that the absorption-type merger, with Chugai as the surviving company and Renalys Pharma, Inc. as the dissolving company, was completed on December 30, 2025.
[Reference]
Notice of Absorption-Type Merger of a Wholly-Owned Subsidiary, Renalys Pharma, Inc. (News release issued on November 18, 2025)
https://www.chugai-pharm.co.jp/english/news/detail/20251118173000_1199.html
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp